GAS5 and glioblastoma: GBM sections derived from the patient who was non-tolerant to adjuvant therapy (P2) showed preferential GAS5 expression in these hypoxic regions compared to its expression in more structurally intact tumor cells (39% increase; P2; Figure 5A,B).